Insights
Insights From Our Experts
Articles
Achieve Price and Access Launch Excellence in a Disrupted World
With the U.S. election behind us, the soaring costs of U.S. healthcare have become a priority for politicians—in particular, the cost of prescription drugs. Some proposed solutions involve external reference pricing from comparable countries and limiting drug price increases. These anticipated changes in U.S. pricing policy, coupled with the downward pressure on…
Insights From Dreamforce 2020 Panel: End-To-End Patient Engagement
EVERSANA was proud to participate in this year’s brand-new session “End-To-End Patient Engagement: From Clinical Trials Through Patient Support Programs.“ Bhaskar Sambasivan, Chief Strategy Officer and President of Patient Services, provided valuable insight into the emerging…
Insights From Trade & Channel Strategies Conference 2020
Now more than ever, pharma manufacturers need to break the cycle of supply chain complexity to better connect patients to therapy. On Tuesday, December 1, EVERSANA’s Scot Buchanan moderated the panel “Emerging and Future Trends in Channel…
DSCSA Guidelines – Best Practices for Compliance and Supply Chain Integration
On November 27, 2023, all drug manufacturers must participate in an electronic package-level traceability system, commonly known as the “interoperability” requirement. EVERSANA is equipped to help manufacturers navigate these new guidelines and apply best practices. Let’s…
EVERSANA Receives PM360 Innovations Award for Seamlessly Disrupting Commercialization
EVERSANA’s end-to-end commercialization solution is reimagining traditional pharmaceutical commercialization models for the first time by breaking down industry service silos with integrated approaches and advanced technologies. PM360‘s Annual Innovation Issue was established in 2011 to provide pharma with its first-ever guide to the life sciences industry’s…
COVID-19 Vaccine Safety Briefing Report
Posted by Lisa Rinker, Nina Patel Lahanis, Shraddha Bhange, MD, MBBS, Msc. on December 9, 202012/9/20
As the world awaits the fast-approaching rollout of an approved COVID-19 vaccine, developing the planning to order, distribute and track COVID-19 vaccines in the United States and globally presents an unprecedented challenge. The Food and Drug…
Applying the Scientific Method as the Cornerstone of Brand Insights and Strategy
Commercial leaders across biopharmaceutical companies invest millions of dollars each month on developing insights to inform their understanding of the market and their own brand ambition, determining where to play and how to win. And it is no…
A New Pharmaceutical Strategy for Europe
In late November, the European Commission announced the adoption of a new healthcare plan – the Pharmaceutical Strategy for Europe. This plan aims to strengthen the European Health Union while ensuring affordable patient access across the…
What Happens After a COVID-19 Vaccine Trial Succeeds? 4 Pharmacovigilance Challenges to Address During Commercialization
As pharma companies continue to develop COVID-19 vaccines around the world, they are faced with these questions: What happens when we succeed? How will we quickly and safely distribute the vaccine globally? Pulling off this rapid,…
Solving Hard Go-To-Market Challenges [Webinar]
How can looking outside the box help identify innovative approaches that achieve market objectives? Today, in a world where pharma is shifting away from primary–care blockbusters and embracing specialty–care products, looking outside the box is essential. Focusing on HCPs during a product launch is no longer…